Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.46 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMO | Q99835 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1008151 | 1.00 | P2RX7 (0.46) | P2RX7EHMT2BRD4HCRTR1HCRTR2 | |
| SCHEMBL1189963 | 1.00 | P2RX7 (0.46) | P2RX7EHMT2BRD4HCRTR1HCRTR2 | |
| SCHEMBL2341733 | 0.85 | HCRTR1 (0.42) | EHMT2BRD4HCRTR1HCRTR2MEN1 | |
| SCHEMBL537384 | 0.85 | EHMT2 (0.41) | P2RX7EHMT2BRD4HCRTR1HCRTR2 | |
| SCHEMBL1459146 | 0.82 | HCRTR1 (0.52) | HCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL697331 | 0.82 | HCRTR1 (0.52) | HCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL3508819 | 0.82 | HCRTR1 (0.52) | HCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL6133226 | 0.82 | P2RX7 (0.45) | P2RX7EHMT2HCRTR1HCRTR2MEN1 | |
| SCHEMBL6133023 | 0.82 | P2RX7 (0.45) | P2RX7EHMT2HCRTR1HCRTR2MEN1 | |
| SCHEMBL3333497 | 0.81 | P2RX7 (0.46) | P2RX7EHMT2HCRTR1HCRTR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2362775-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2362775-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-1856058-B1 | PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8697685-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| EP-2362775-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-09-07 | — | — | EP | disclosed |
| US-7863271-B2 | 2-aminobenzoxazole carboxamides as 5HT3 modulators | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| WO-2010120854-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010120854-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-10-21 | — | — | WO | disclosed |
| US-7759337-B2 | Phthalazine compounds and methods of use | AMGEN INC. (US) | 2010-07-20 | — | — | US | disclosed |
| WO-2010059658-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059658-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| US-20080255114-A1 | 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | AMR TECHNOLOGY, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20060199817-A1 | Phthalazine, aza- and diaza-phthalazine compounds and methods of use | AMGEN INC. (US) | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199817-A1 | Phthalazine, aza- and diaza-phthalazine compounds and methods of use | DAPK2, CDK2, DAPK1 | P2RX7 520/4885EHMT2 595/4885BRD4 813/4885 |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | PDK1, PDK2, PDK3 | P2RX7 3009/4885EHMT2 3060/4885BRD4 818/4885 |
| US-20080255114-A1 | 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | HTR3E, HTR3C, HTR3A | P2RX7 363/4885EHMT2 3630/4885BRD4 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.